Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited and Provides Corporate Update
Common stock of the merged company, Clene Inc., to commence trading on the NASDAQ Capital Market under the ticker symbol “CLNN” on December 31, 2020
Clinical pipeline includes an ongoing Phase 3 study in amyotrophic lateral sclerosis (ALS) and four concurrent Phase 2 studies in ALS, multiple sclerosis and Parkinson’s disease
Proceeds from the transaction totaled approximately $31.9 million, combining funds held in Tottenham’s trust account and a concurrent $22.4 million PIPE financing
SALT LAKE CITY, Dec. 30, 2020 (GLOBE NEWSWIRE) Clene Nanomedicine, Inc. (“Clene”) (NASDAQ: CLNN), a clinical-stage biopharmaceutical company, today announced the closing of a merger with Tottenham Acquisition I Limited (“Tottenham”) and provided a corporate update. Proceeds from this transaction totaled approximately $31.9 million, which included funds held in Tottenham’s trust ac
good morning, welcome to today on a monday morning. i m matt lauer. good morning, everyone. i am savannah guthrie. we ve heard about the rescue of the three women in cleveland and for the first time we get to see what happened at the house of horrors one week ago. we re learning more about the possible defense strategies that could be used by the suspect in this case. let s get to today national investigative correspondent jeff rossen. he s in cleveland. jeff, good morning to you. reporter: matt, savannah, good morning to you. a lot to get to this morning, including ariel castro sitting in this 9 by 9 jail cell beginning to map out his defense strategy. there are other big headlines over the weekend as well. ariel castro s brothers, arrested and cleared by police they re speaking out for the first time. what do they have to stay about their brother? and, of course, that dramatic video you mentioned, taking you inside the moment police officers rushed up this side